Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lantheus Holdings Inc LNTH

Healthcare Medical Instruments & Supplies
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic... see more

Recent & Breaking News (NDAQ:LNTH)

Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform

GlobeNewswire December 12, 2022

Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027

GlobeNewswire December 6, 2022

Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027

GlobeNewswire December 5, 2022

Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial

GlobeNewswire November 29, 2022

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China's NMPA

GlobeNewswire November 28, 2022

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

GlobeNewswire November 14, 2022

Lantheus to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 9, 2022

Lantheus Reports Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time

GlobeNewswire October 20, 2022

Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data

GlobeNewswire October 17, 2022

Targa Resources Set to Join S&P 500; Lantheus Holdings to Join S&P MidCap 400; Payoneer Global to Join S&P SmallCap 600

PR Newswire October 6, 2022

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

GlobeNewswire September 13, 2022

Lantheus to Present at the Wells Fargo Healthcare Conference

GlobeNewswire September 1, 2022

Lantheus Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time

GlobeNewswire July 21, 2022

Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer

GlobeNewswire June 15, 2022

Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer

GlobeNewswire June 13, 2022

Lantheus' PYLARIFY AI(TM) Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer

GlobeNewswire June 13, 2022

Lantheus to Present at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI(TM) and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

GlobeNewswire May 26, 2022